BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/4/2026 7:19:44 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-02-06 02:23 |
|
Peer-Review Started |
|
2026-02-06 02:25 |
|
First Decision by Editorial Office Director |
|
2026-03-06 09:28 |
|
Return for Revision |
|
2026-03-06 09:28 |
|
Revised |
|
2026-03-16 04:12 |
|
Publication Fee Transferred |
|
2026-03-20 08:36 |
|
Second Decision by Editor |
|
2026-04-15 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-15 09:07 |
|
Articles in Press |
|
2026-04-15 09:07 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-09 09:48 |
|
Publish the Manuscript Online |
|
2026-08-04 07:19 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Run-Ling Zhang, Hai-Ying Zhang, Yu-Yuan Jia, Zhen-Yu Wang, Feng Liu, Hong-Song Chen and Hui-Ying Rao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hui-Ying Rao, Professor, Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, No. 133, Fuchengmennei Street, Xicheng District, Beijing 100044, China. rao.huiying@163.com |
| Key Words |
Low-level viremia; Nucleos(t)ide analogs; Chronic hepatitis B; Compensated cirrhosis; Risk factor |
| Core Tip |
Our retrospective study enrolled 141 chronic hepatitis B (CHB) patients with advanced hepatic fibrosis/compensated cirrhosis undergoing tenofovir disoproxil fumarate therapy, with the incidence of low-level viremia (LLV) reaching 17.0% at 48 weeks of treatment. Multivariate logistic regression analysis confirmed that baseline hepatitis B virus DNA ≥ 7.0 Log10 IU/mL was an independent high-risk factor for LLV development. This finding provides comprehensive clinical evidence for early risk stratification and individualized intervention of LLV in this specific high-risk CHB population. |
| Publish Date |
2026-08-04 07:19 |
| Citation |
Zhang RL, Zhang HY, Jia YY, Wang ZY, Liu F, Chen HS, Rao HY. Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis. World J Gastroenterol 2026; 32(31): 119706
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i31/119706.htm |
| DOI |
https://doi.org/10.3748/wjg.119706 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
